Please login to the form below
mergers
This page shows the latest mergers news and features for those working in and with pharma, biotech and healthcare.
Roche and Novartis part ways with share purchase
a possible merger. ... The proposed merger, masterminded by ex-Novartis CEO Daniel Vasella, was vetoed by the Hoffman-La Roche family that controls Roche.
Latest news
-
Merck to acquire Acceleron in a deal worth around $11.5bn
The merger rumours started late last week when it was reported that a large pharma group was close to agreeing a $180 per share bid that would value Acceleron at $11bn.
-
Mysterious big pharma company eyes US biotech Acceleron
The merger rumours started late last week when it was reported that a large pharma group was close to agreeing a $180 per share bid that would value Acceleron at $11bn.
-
Sanofi boosts transplant portfolio with newly approved Rezurock
The “definitive merger agreement” will see Kadmon shareholders receive $9.50 per share in cash – a 79% premium on its closing price – in a deal worth $1.9 billion in total
-
AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance
The proposed deal is still waiting for regulatory clearance in the UK, which is a requirement for the completion of the merger. ... At the time, the CMA said it would be inviting comments from interested parties to aid in its assessment of the merger –
-
Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug
Early-stage biopharma company Pardes Biosciences is set to go public through a merger with special purpose acquisition company (SPAC) FS Development Corp II to advance the development of its oral ... Through the merger deal, Pardes will receive
More from news
Approximately 110 fully matching, plus 482 partially matching documents found.
Latest Intelligence
-
Integrating competitive intelligence into business development, licensing and M&A strategy
and mergers and acquisitions (M&A). ... One could think of larger companies as acquirers and smaller companies as acquirees in such transactions, but in many cases larger companies are acquired in mega-mergers, and small companies frequently
-
Transforming clinical trial data into a long-term asset
On the corporate side, it can come into play in licensing and partnership opportunities, in handling legal challenges and due diligence, and in mergers and acquisitions.
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
the pipeline, the use of technology in medicine is expected to grow and so are the associated deals, mergers and acquisitions. ... They also can help identify collaboration opportunities including partnerships, licensing deals and merger or acquisition
-
Rebranding in an evolving world
It goes without saying that partnerships are a fundamental part of that portfolio expansion, which is why another key area of investment has been in mergers and acquisitions.
-
Pharma funding and M&A in 2020
Mega mergers. However, the flip side of new disruptors entering a sector is that the established players will of course seek to defend their positions. ... It’s unsurprising, therefore, that in recent years we’ve seen a number of mega mergers.
More from intelligence
Approximately 75 fully matching, plus 52 partially matching documents found.
Latest appointments
-
Ashfield Advisory adds Mary-Kate McGarry and Emer Jameson to senior leadership team
At Ashfield Advisory, she will be responsible for driving all aspects of the company’s strategy and will work closely with the mergers and acquisitions team, while also oversee the
-
McCann Health North America appoints Jim Joseph as president
During his time serving as global president at BCW, he helped lead the complex merger of Burson Marsteller with Cohn &Wolfe.
-
New hires at Bayer, Eisai and Accord Healthcare
Marianne De Backer is a recognised business leader with an impressive track record spanning over two decades in research and commercial, as well as licensing, mergers and acquisitions,” said Stefan Oelrich,
-
Changes at Oxford PharmaGenesis, Reynolds-Mackenzie and more
2019 represents an exciting year for Reynolds-MacKenzie and Open Health, fuelled by the recent merger with Peloton Advantage in the US.
-
New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics
Cerato brings with him a wealth of business development experience, including in-licensing, out-licensing, alliance management, and mergers and acquisitions.
More from appointments
Approximately 0 fully matching, plus 53 partially matching documents found.
Latest from PMHub
-
MAKING THE FIRST YEAR MATTER
Since the launch of its new proposition in January 2021 following the merger of Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing, the UK Mind Matter team, led by Corrina Safeio,
-
OPEN Health Acquires ARK
The merger enhances and supports OPEN Health’s positioning – deep, broad, and united:.
-
OPEN Health acquires UK medical communications agency Spirit
The merger enhances OPEN Health’s positioning – deep, broad, and united:.
-
Lucid Group acquires US-based strategic brand consultants DiD
Lucid Group has acquired the US-based strategic brand consultants, DiD. This union will strengthen Lucid Group’s existing presence in the US and its ability to provide a compelling strategic, creative and digital offering globally. It is a large
-
Pharmerit rebrands to OPEN Health
Since its inception in 2011, OPEN Health has expanded its expertise and global reach through mergers and organic growth to be at the forefront of the healthcare industry.
More from PMHub
Approximately 2 fully matching, plus 19 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
